Protara Therapeutics (TARA)
(Delayed Data from NSDQ)
$3.19 USD
-0.02 (-0.62%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $3.18 -0.01 (-0.31%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TARA 3.19 -0.02(-0.62%)
Will TARA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TARA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TARA
Protara Therapeutics (TARA) Moves to Buy: Rationale Behind the Upgrade
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy
TARA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TARA
Is TARA ready to move higher? 20 Day Moving Average Support shows up after sliding 0.62%
Analysts Predict Up to 840% Jump for These 2 ‘Strong Buy’ Penny Stocks
Crossed Above 20 Day Moving Average appears for TARA after 5.94% move
Stochastic Reached Oversold appears for TARA after 1.3% move
Citizens JMP healthcare analysts hold an analyst/industry conference call